艾迪注射液对乳腺癌患者血清VEGF水平的影响

目的观察艾迪注射液对乳腺癌患者血清血管内皮生长因子（VEGF）的影响，探讨其对乳腺癌的治疗作用。方法46例乳腺癌患者随机分为对照组（单纯化疗）、实验组（化疗加艾迪注射液），每组23例。另收集30例健康人做为健康对照组。应用双抗体夹心EMSA法检测两组乳腺癌患者治疗前后血清VEGF水平变化。结果化疗前乳腺癌患者血清VEGF水平明显高于对照组（P〈0．01），其水平与患者年龄、肿瘤大小、组织学分级无关（P均〉0．05），与患者淋巴结转移、临床分期有关（P均〈0．01）。新辅助化疗前乳腺癌患者血清VEGF明显高于健康对照组（285．17±57．58）pg／ml傩（152．17±26．45）pg/ml，P〈0．01]；实验组治疗前、后血清VEGF水平分别为（289．30±61．50）、（210．13±52．12）pg／ml，差异有统计学意义（P〈0．01）；对照组治疗后血清VEGF水平与治疗前相比差异无统计学意义（P〉0．05）；实验组治疗后VEGF水平低于对照组（210．13±52．12）pg／mlvs（261．46±54．29）pg／ml，P〈0．01]。结论艾迪注射液可以降低乳腺癌患者血清VEGF水平，通过抑制肿瘤血管生成进而抑制肿瘤细胞的增殖、浸润及转移，从而发挥抗肿瘤作用，在乳腺癌辅助抗肿瘤治疗中起着重要作用。

Effect of Aidi injection on serum VEGF in patients with breast cancer

Objective To observe the influence of Aidi injection on serum vascular endothelial growth fac- tor （VEGF） in patients with breast cancer and study its effect on anti - tumor therapy. Methods Forty-six patients with breast cancer,were randomly divided into two groups （n = 23 each） ： test group （treated by chemotherapy com- bined with Aidi Injection） and control group （treated by chemotherapy only）. 30 healthy subjects were chosen as health control group. The changes of serum VEGF levels of breast cancer patients before and after treatment were de- tected by double antibody sandwich enzyme - linked immunosorbent assay （DAS-ELISA）. Results The serum VEGF levels of breast cancer patients before chemotherapy were significantly higher than that of health control group （285.17 ~57.58） pg/ml vs（152.17 ~26.45） pge/ml, P 〈0.01]. VEGF levels of breast cancer patients were closely related to lymph node metastasis and clinical staging （all P 〈 0.01 ）, but were not related to age, size and histological grade of the tumors （ all P 〉 0.05 ）. The serum levels of VEGF after treatment in test group were signifi- cantly lower than that before treatment （210.13 ＋52.12）pg/ml vs （289.30 ~61.50） pg/ml, P 〈0.01 ] and low- er than that in control group （210.13 ~ 52.12） pg/ml vs （261.96 ~ 54.29） pg/ml, P 〈 0.01 ]. There was no sig- nificant difference in serum ~EGF levels before and after treatment in control group （ P 〉 0.05）. Conclusions Aidi injection can reduce the serum VEGF level in patients with breast cancer, thereby gives play to anti -tumor through inhibiting forming of tumor vessels further inhibiting proliferation, infiltration and metastasis of tumor cells, and Aidi injection adjunctive therapy plays an important role in the treatment of anti-tumor of breast cancer.